Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand Pharmaceuticals (LGND) presented a royalty-driven growth strategy, emphasizing a larger commercial-stage asset base following its XOMA acquisition. Management also outlined portfolio catalysts and planned investment capacity, framing the outlook as supportive for future royalty/operating growth. The update is constructive but appears incremental rather than a major near-term catalyst.